Abstract
Assays for the activated form of thrombin activatable fibrinolysis Inhibitor(a) (TAFIa) can measure the extent of TAFI activation in patient populations. TAFI is a human plasma zymogen that is related to pancreatic carboxypeptidase B (CPB). The active form of TAFI (TAFIa), formed by thrombin cleavage of the zymogen, likely inhibits fibrinolysis by removal of the carboxyl-terminal lysine residues of partially degraded fibrin that stimulate plasminogen activation. TAFI is encoded by the CPB2 gene (chromosome 13) [Boffa MB et al. Biochemistry 1999]. This article presents insights into the function and regulation of TAFI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
